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We  review and demonstrate how an empirical Bayes method, shrinking a protein’s sample
variance towards a pooled estimate, leads to far more powerful and stable inference to detect
signiﬁcant changes in protein abundance compared to ordinary t-tests. Using examples from
isobaric mass labelled proteomic experiments we show how to analyze data from multiple
experiments simultaneously, and discuss the effects of missing data on the inference. Wenference
rotein abundance
also  present easy to use open source software for normalization of mass spectrometry data
and inference based on moderated test statistics.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
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lihood and estimating a rather large number of parameters..  Introduction
etecting signiﬁcant changes in protein abundance is a funda-
ental task in mass-spectrometry based experiments when
rying to compare treated to untreated cells, wildtypes to
utants, or samples from diseased to non-diseased subjects.
he statistical inference for proteomic data in these settings
s usually based on standard 2-sample t-tests, comparing the
easured relative or absolute abundances for each peptide
r protein across the conditions of interest. However, sample
izes are often small, sometimes as small as 4 or 8 samples
otal, which result in great uncertainty in the sample vari-
bility estimates. Since these estimates are used in the test
tatistics to assess the statistical signiﬁcance of the observed
old change, proteins exhibiting a large fold change are often
eclared non-signiﬁcant because of a large sample variance,
hile at the same time small observed fold changes might
e declared statistically signiﬁcant, because of a small sample
ariance.
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Additional methods to assess biological and technical
sources of variability have been proposed [1–6], including
methods to analyze data from multiple experiments simulta-
neously. For case–control iTRAQ experiments, Oberg et al. [7]
and Hill et al. [8] extended a linear mixed effects approach
originally proposed by Kerr and Churchill [9,10] as analysis
of variance for gene expression studies. This mixed model
adjusts for potential differences due to channel effects, load-
ing, mixing, and sample handling. The parameter of interest
in the model is the interaction between protein and group sta-
tus, with a statistically signiﬁcant result indicating differential
expression (abundances) between cases and controls. One  of
the noteworthy features of this approach is that it simulta-
neously estimates protein relative abundance and assesses
differential expression, albeit with substantial computational
cost due to the numerical complexity of optimizing the like-Herbrich et al. [11] demonstrated that estimating protein
abundances using median sweeps reduces computational
cost substantially, and is as efﬁcient yet more  robust than
 European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/4.0/).
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protein abundance estimation procedures based on linear
mixed effects models.
An implicit assumption in the approach of Oberg et al.
[7] and Hill et al. [8] is that the biological variability is the
same for all proteins identiﬁed and quantiﬁed. Though “all
models are wrong, but some are useful” [12], incorrect model
assumptions can lead to a loss in power even if no bias is
incurred. This was for example observed in gene expression
studies when LIMMA  (“Linear Models for Microarray Data”) [13]
was introduced as an empirical Bayes approach that speciﬁ-
cally allowed for a realistic distribution of biological variances,
compared to the models of Kerr and Churchill [9,10], which
assumed constant variability. The statistical trick in LIMMA
is to use the full data to shrink the observed sample vari-
ances towards a pooled estimate. This results in far more
stable and powerful inference compared to ordinary t-tests
particularly when the number of samples is small [13], yet still
allows for a distribution of variances. LIMMA arguably is the
contemporary analytical standard for gene expression experi-
ments, as evidenced by over 6000 citations in the last ten years
(http://scholar.google.com). LIMMA  has also been sporadically
used in the context of proteomic experiments [14–19], but is
far from being regarded as the analytical standard. This is sur-
prising since proteomic experiments often have somewhat
small sample sizes, and for those the potential gains of an
empirical Bayes procedure are highest. One possible explana-
tion for this phenomenon (besides being originally developed
for a different genomic application) might be that LIMMA has
been implemented as a Bioconductor package in the language
R, a statistical environment the proteomics community only
recently started to embrace [20–26].
In this manuscript we  use examples from quantitative pro-
teomic experiments using isobaric mass tags to demonstrate
how better results in case–control studies can be achieved by
using the LIMMA  moderated test statistics. We  show how to
analyze data from multiple experiments simultaneously, and
discuss the effects of missing data on the inference. We  give
sufﬁcient detail for the statistically inclined reader to under-
stand what happens “under the hood” of this empirical Bayes
approach, and also present easy to use open source software
for the practitioner to carry out the normalization of these
mass spectrometry data, and to readily obtain the inference
from moderated test statistics.
2.  Materials  and  methods
2.1.  Sample  description
The data stem from two Trypanosoma brucei transgenic cell
lines overexpressing either TbHslV-wild type or TbHslV-
mutant protease. The T. brucei mitochondrion contains a
proteasome-like ATP-dependent protease named TbHslVU
that plays a critical role in regulating the timing of mitochon-
drial DNA replication [27]. Previous experiments suggested
that TbHslVU controls the timing of kDNA synthesis by degrad-
ing “positive regulator of replication” [27,28]. To search for
TbHslVU substrates its catalytically active subunit (denoted
as TbHslV-wt)  and its catalytically dead mutant (denoted as
TbHslV-mt)  were fused to the tandem afﬁnity puriﬁcation s 7 ( 2 0 1 5 ) 11–19
(TAP) tag. TAP-tagged TbHslV-wt or TbHslV-mt overexpress-
ing cell lines were generated and the overexpressed proteins
were puriﬁed using a TAP protocol adapted from Ringpis [29].
TbHslV-wt and TbHslV-mt were performed in four independent
biological replicates.
Quantitative mass spectrometry was used to identify pro-
teins that are associated with overexpressed and puriﬁed
TbHslV-mt but not with TbHslV-wt treated similarly; since
the latter binds and degrades its substrates. Proteins were
digested with trypsin, labelled using the eight-plex iTRAQ iso-
baric mass tags (ABSciex) and analyzed using tandem mass
spectrometry on an LTQ Velos Orbitrap interfaced with an
Eksigent 2D NanoLC as previously described [11,30,31], except
mass tagged peptides were fractionated by basic reverse phase
chromatography [32]. Peptides were identiﬁed using Proteome
Discoverer v1.4 (Thermo Scientiﬁc, San Jose, CA) and Mascot
v2.2 (Matrix Sciences). Software defaults were used to control
the false discovery rate (FDR) and only peptides spectra with
less than 1% FDR and less than 30% isolation interference were
included in analysis.
Protein log 2 relative abundances were estimated using the
method of Herbrich et al. [11]. In this procedure, a logarith-
mic  transformation of the reporter ion intensities is employed
since systematic effects and variance components are usually
assumed to be additive on this scale [7,8]. The log 2 reporter
ion intensities for each spectrum are “median-polished” by
subtracting the spectrum median log 2 intensity from the
observed log 2 intensities. The relative abundance estimate
for a particular protein is calculated as the median of these
residuals, from all reporter ion intensity spectra belonging to
this protein. Corrections for differences in amounts of mate-
rial loaded in the channels and sample processing are carried
out by subtracting the channel median from the relative abun-
dance estimate, normalizing all channels to have median zero.
2.2.  Statistical  inference
2.2.1.  Two  group  comparisons
To detect differentially expressed proteins in a balanced pro-
teomic experiment with n cases (log 2 relative abundances X1p,
. . ., Xnp for protein p) and n controls (log 2 relative abundances
Y1p, . . .,  Ynp), inference is typically based on a 2-sample t-test
for each protein p, with test statistic
tp = estimated log fold changeestimated standard error =
Xp − Yp
sp
√
2/n
, (1)
where Xp and Yp are the group mean log 2 relative abundances,
and
sp =
√∑
i
(Xip − Xp)2 +
∑
i
(Yip − Yp)2
2n − 2 (2)
is the within-group sample standard deviation. For each pro-
tein, a p-value is then calculated referring the test statistic
tp to a t-distribution with dp = 2 × n − 2 degrees of freedom as
null distribution. For the above the log 2 relative abundances
are assumed to be normally distributed with equal variance in
each group, although t-tests are robust to departures from the
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testing for differential expression, if a protein has a q-value of
0.10, we expect 10% among the proteins that show smaller p-e u  p a o p e n p r o t e o 
ormality assumption unless outliers are present and sample
izes are small [33]. Similar test statistics can be calculated for
on-equal group variances and unbalanced experiments.
.2.2.  Moderated  statistics
he above approach estimates the variance s2p and the
tandard error sp
√
2/n for each protein separately (Eqs. (1)
nd (2)), and does not use information (such as experi-
ental precision) shared across all proteins. An alternative
pproach “Linear Models for Microarray Data” (LIMMA) [13],
lso applicable for mass-spectrometry based high throughput
xperiments, uses the fact that under a normality assumption
or the log 2 relative abundances the sample variance follows
 scaled 2 distribution
2
p|2p∼
2p
dp
× 2dp , (3)
here 2p is the true (unknown) variance, and dp are the
egrees of freedom associated with the experiment. In con-
rast to the ordinary 2-sample t-test where 2p is regarded as a
xed (but unknown) parameter, LIMMA  is an Empirical Bayes
rocedure where the protein variances are assumed to follow
 scaled inverse 2 distribution
1
2p
∼ 1
d0 × s20
× 2d0 . (4)
he parameters d0 and s20 are estimated from the observed
ata via maximum likelihood. Using such as a scaled inverse
2 distribution for the protein variances implies that the set
f protein sample variances s2 follows a scaled F distribution
13], e.g.
2∼s20 × Fdp,d0 . (5)
nder the above hierarchical model, the posterior for a pro-
ein’s sample variance is moderated: the observed protein
ample variance s2p is shrunk towards the common prior value
2
0, with the magnitude of shrinkage depending on the relative
izes of the observed and prior degrees of freedom dp and d0:
2
p [moderated]
=
dp × s2p + d0 × s20
dp + d0
=  × s2p + (1 − ) × s20
with  = dp
dp + d0
∈ (0,  1).  (6)
hus, the shrinkage of the sample variance s2p towards a com-
on  mean s20 will be most pronounced when few data are
vailable, as dp and therefore  will be small. The p-values are
hen derived referring the moderated t-statistic
p [moderated] =
estimated log foldchange
moderated standard error
= Xp − Yp
sp [moderated]
√
2/n
(7)o a t distribution with dp + d0 degrees of freedom. Note that
nly the estimates of the standard errors change, and the
stimated log fold changes in the numerator remain the same. 7 ( 2 0 1 5 ) 11–19 13
2.2.3.  Multiple  experiments
To achieve a desired sample size it is often necessary to carry
out multiple experiments. These data can be analyzed by
expanding the two-sample t-test into a more  general linear
model framework. For example, the regression for two  8-plex
iTRAQ experiments can be written as
E
[
Zpijk
]
= ˛p + p × 1{i=1} + p × 1{k=2} (8)
where Zpijk denotes the measured log 2 relative abundances of
protein p in sample j ∈ {1, . . ., 4} under condition i ∈ {0, 1} in
experiment k ∈ {1, 2}, i.e. 4 mutants and 4 wildtypes in each of
two experiments (the 1 in Eq. (8) denotes the standard indi-
cator function). For more  than two experiments, the above
equation can simply be expanded by allowing more  param-
eters to indicate the extra experiments, or a mixed effects
model can be used with a random effect for the experiment
[7,8,11]. The inference to assess differential expression is on
the parameter p, the expected difference in log 2 relative
abundances of protein p when comparing a mutant and a
wildtype from the same experiment. Statistical signiﬁcance
is based on the observed fold change, and an estimate of its
standard error. The latter can be derived by estimating the
variability separately for each protein. Alternatively, LIMMA
also allows for pooling information across all proteins within
the above linear model framework, generating moderated t-
statistics and p-values [13].
2.2.4.  Multiple  comparisons
Since hundreds or even thousands of proteins can be identiﬁed
and quantiﬁed in a typical mass spectrometry experiment,
multiple comparisons corrections are imperative. The most
popular procedure is the Bonferroni correction which con-
trols the family wise error rate (FWER), that is, the probability
of at least one type I error (i.e. false positive). Only proteins
with nominal p-value less than ˛/N are declared differentially
expressed, where  ˛ is the desired FWER (typically, 5%), and
N is the number of proteins assessed. The consequence of
such a strong protection against any false positives is usually
a large number of false negatives, that is truly differentially
expressed proteins not declared signiﬁcant. Thus, in high-
throughput experiments with potentially many  differentially
expressed proteins, a more  desirable parameter arguably is the
false discovery rate (FDR), designed to control the proportion
of false positives among a set of proteins declared differen-
tially expressed. The original FDR approach by Benjamini and
Hochberg [34] was extended by Storey [35–37] to so-called “q-
values”, which have a similar interpretation for the FDR  as
p-values have for type-I error control: the q-value for a pro-
tein is deﬁned as the minimum FDR that can be attained (i.e.,
the expected proportion of false positives incurred) when call-
ing that protein differentially expressed. In other words: whenvalues to be false positives. The q-values are calculated from
the observed p-values after estimating the proportion of dif-
ferentially expressed proteins in the experiment (see Storey
and Tibshirani [37] for details).
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2.3.  Simulations
To compare the performances of the ordinary 2-sample t-tests
and the empirical Bayes moderated t-tests with regards to
power and type I error (true and false positives), we  simulated
data mimicking the above described T. brucei 8-plex iTRAQ
experiment with 4 mutants and 4 wildtypes. The log 2 relative
abundances of mutants and wildtypes for 1394 proteins were
generated from a normal distribution with variances accord-
ing to the scaled inverse 2 distribution (Eq. (4)) with estimated
parameters d0 = 4.43 prior degrees of freedom and a scaling
factor of s20 = 0.032 (Supplementary Fig. 1). The means of the
normal distributions were chosen to reﬂect the desired fold
changes in the respective simulations. A 50% fold change was
used in all simulations when only a single experiment was
considered, and both 25% and 50% fold changes were used in
separate simulations when multiple experiments were ana-
lyzed.
2.4.  Software
A software vignette to carry out the analyses described in
this manuscript and to reproduce the simulations is avail-
able at www.biostat.jhsph.edu/∼kkammers/software/eupa/.
The software is freely available as Free Software under the
terms of the Free Software Foundation’s GNU General Public
License in source code form.
3.  Results
A total of 2047 proteins were identiﬁed and quantiﬁed in the
T. brucei 8-plex iTRAQ experiment. To reduce the impact of
possible false positive identiﬁcations, we  only retained the
1394 proteins with 2 or more  peptides quantiﬁed. With an
ordinary 2-sample t-test to assess differential expression we
ﬁnd that most of the statistically signiﬁcant differences were
from proteins with little sample variability (Fig. 1A). Among
the 1394 proteins, 258 (18.5%) achieved nominal signiﬁcance
at a 5% level, but only one protein was declared differen-
tially expressed after multiple comparisons correction using
the Bonferroni method (Fig. 1B). Notably, this protein had
very small sample variability (8th smallest among the 1394
proteins). While only few more  proteins were nominally sig-
niﬁcant at a 5% level when using moderated t-statistics (277,
19.9%), seven proteins achieved statistical signiﬁcance after
Bonferroni correction (p < 3.6 × 10−5, Fig. 1C). Moreover, at a
FDR of 1% (i.e. q < 0.01) only 1 protein is declared differentially
expressed when using ordinary test statistics, compared to
23 proteins declared differentially expressed when moderated
test statistics are employed (FDR of 5%: 30 and 98 proteins,
respectively; FDR of 10%: 120 and 184 proteins). Thus, at the
same error level many  more  proteins can be declared differen-
tially expressed when using the moderated compared to the
ordinary t-statistics. This improvement is achieved by shrink-
ing particularly the extreme variances towards a common
mean (Supplementary Fig. 2). As a consequence, compared to
their ordinary test statistics, proteins with low sample vari-
ability have less signiﬁcant moderated test statistics, proteins
with large sample variability have more  signiﬁcant moderated s 7 ( 2 0 1 5 ) 11–19
test statistics, and test statistics from proteins with moderate
sample variability remain largely unchanged (Supplementary
Fig. 3).
In a simulation study with ten differentially expressed pro-
teins (50% fold change) we visualize how the differentially
expressed proteins become more  signiﬁcant when moder-
ated test statistics are used (Fig. 2A and B, green dots), while
spurious associations with small observed fold changes tend
to become less signiﬁcant (Fig. 2A and B, yellow dots). This
improvement in detecting differentially expressed proteins
through moderated test statistics is not owed to an overall
increase in false positives, as both the ordinary 2-sample t-
test and the moderated t-test properly control the type I error
(Fig. 2C and D). To quantify the potential gains in true discov-
ery while maintaining error control via the FDR, we  increased
the number of differentially expressed proteins to 100 and
averaged the results over 1000 iterations. For all levels of FDR
control between 1% and 10%, the empirical Bayes approach
using moderated test statistic produces substantially larger
lists of proteins declared differentially expressed, detecting
more truly differentially expressed proteins while maintain-
ing proper error control (Fig. 3, left). Displaying the results on
a receiver operating characteristic (ROC) curve, we  ﬁnd that at
equal false positive rates the true positive rate is substantially
higher when using moderated test statistics (Fig. 3, right).
Equivalent results were obtained when multiple exper-
iments were analyzed simultaneously. We simulated three
replicate 8-plex iTRAQ experiments with 100 differentially
expressed proteins using the same parameters for the vari-
ability as above, and analyzed the data using the linear model
displayed in Eq. (8). We used both ordinary test statistics
(analyzing each protein separately) and the moderated test
statistics using LIMMA. We recorded false positives and false
negatives for a variety of signiﬁcance thresholds, and averaged
the results over 1000 iterations. Since the power to detect dif-
ferentially expressed proteins increases with the number of
experiments, we  also show the ﬁndings for lower fold changes.
For all false positive rates between 0.5% and 10% considered
and fold changes of 25% and 50%, the true positive rate (sen-
sitivity) was again higher when using the empirical Bayes
approach with moderated test statistics (Fig. 4). In addition,
we simulated experiments with three replicates and randomly
selected 10% of proteins as missing in each experiment. While
the presence of missing data generally results in a loss of
power to detect differentially expressed proteins, these data
can still be analyzed using linear models with moderated test
statistics and proper type I error control. The ﬁndings for
this setting were the same, supporting the variance shrink-
ing approach as more  powerful (Fig. 4). In particular, in the
presence of missing data, the amount of shrinkage of the vari-
ance depends on the actual observed experimental degrees of
freedom (Supplementary Fig. 4).
4.  DiscussionIdentifying differentially expressed proteins is a task in pro-
teomic studies commonly carried out simply using t-tests. In
this manuscript we demonstrated how better results can be
achieved by using moderated t-statistics from the empirical
e u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 11–19 15
Fig. 1 – Inference from an 8-plex iTRAQ experiment with four cases and four controls, with 1394 proteins identiﬁed and
quantiﬁed by 2 or more  peptides. (A) The estimated standard error (x-axis) versus the t-statistics (y-axis) for each protein.
The largest t-statistics (and thus, most signiﬁcant p-values) tend to be from those proteins that show the smallest sample
variability. (B) The volcano plot showing the estimated fold changes (x-axis) versus the − log 10 p-values (y-axis) for each
protein. (C) The volcano plot from the inference based on the moderated t-statistics. Four proteins are highlighted in each
panel, illustrating how proteins with small sample variability can show very low p-values despite small fold changes (red
and yellow), while proteins with larger fold changes do not necessarily show signiﬁcant differential expression (green and
blue). The Bonferroni corrected signiﬁcance level is indicated by the orange line. Pooling information from the
entire distribution of all proteins improves power to detect differentially expressed proteins, and reduces statistical
signiﬁcance of proteins with small sample variability. (For interpretation of the references to colour in this ﬁgure legend, the
r
B
p
o
T
c
l
o
i
l
s
c
f
f
t
w
i
a
(
meader is referred to the web version of this article.)
ayes procedure LIMMA  [13]. This approach shrinks the sam-
le variances used in the estimation of the standard error
f the observed fold changes towards a common mean.
hus, proteins with low sample variability have less signiﬁ-
ant moderated than ordinary t-statistics, and proteins with
arge sample variability have more  signiﬁcant moderated than
rdinary t-statistics. Consequently, statistical signiﬁcance
ncreases for proteins with large fold change and relatively
arge sample variances (affecting the false negative rate) and
tatistical signiﬁcance decreases for proteins with small fold
hange and relatively small sample variances (affecting the
alse positive rate). The observation that proteins with larger
old changes tend to become more  signiﬁcant (Supplemen-
ary Fig. 5) can be even more  pronounced when proteins
ith larger fold changes also tend to have higher variabil-ty even after the logarithmic transformation of the relative
bundances, i.e. when there is a mean-variance relationship
Supplementary Fig. 6). In the manuscript we have presented
ethods and results using isobaric mass labelled quantitativeproteomic experiments, but note that these empirical Bayes
methods are directly applicable in other settings as well. In
fact, they can be used for any technology that yields meas-
ures of peptide or protein abundance, including label-free
experiments.
We also showed how to jointly analyze data from multiple
experiments, a necessity for example in iTRAQ experiments
which limit the number of labels and thus the number sam-
ples that can be run simultaneously. Accounting for possible
between experiment variability is important to maximize
the power to detect differentially expressed proteins, and
LIMMA provides a convenient and powerful framework to do
so simply by specifying the design matrix (which also allows
for experiments with multiple groups, beyond case–control
studies [13]). An alternative approach to analyze data from
multiple experiments, commonly used for example in meta
analyses of genomic data from different studies, is based
on inverse variance weighting (IVW): the observed effect
sizes (fold changes) from different experiments are weighted
16  e u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 11–19
Fig. 2 – Inference for a simulated 8-plex iTRAQ experiment with four cases and four controls, and 1394 proteins. (A) The
volcano plot showing the estimated fold changes (x-axis) versus the − log 10 p-values (y-axis) for each protein. (B) The
volcano plot from the inference based on the moderated t-statistics. The ten proteins simulated with a 50% fold change are
highlighted in green. Pooling information from the entire distribution of all proteins improves power to detect these
differentially expressed proteins. In addition, non-differentially expressed proteins with nominally signiﬁcant p-values
(less than 0.05) and small estimated fold changes (less than 25%) are highlighted in yellow, which highlights how pooling
information from the entire distribution of all proteins reduces the false positive identiﬁcation rate. The quantile–quantile
(QQ) plots for the p-values of the non-differentially expressed proteins based on the ordinary 2-sample t-test (C) and the
moderated t-test (D) show that both approaches properly control the type I error. (For interpretation of the references to
 verscolour in this ﬁgure legend, the reader is referred to the web
by their respective inverse variances, and combined into a
single test statistic. When sample sizes are such that the
individual test statistics approximately follow a normal dis-
tribution, the IVW based test statistic also follows a normal
distribution, and a p-value can readily be calculated. In pro-
teomic experiments with data from few samples such as
8-plex iTRAQ, the test statistics follow t-distributions with
only very few degrees of freedom, and thus are far from
normality. In these settings the p-values have to be based
on permutation tests (such as the one proposed in Storey
et al. [37]) as the null distribution is unknown. In addition
to the computational expense incurred, the procedure is alsoion of this article.)
not very powerful in this setting as the weights themselves
are subject to large variability due to the small sample size.
We found that by ﬁrst using empirical Bayes methods to mod-
erate the variances in each experiment, and thus stabilizing
the weights in the IVW procedure, the power to detect differ-
entially expressed proteins can be greatly improved, although
not up to the same level as the LIMMA model for the simulta-
neous analysis of multiple experiments (data not shown). This
was even true for simulations where the prior scaling factor
s20 was doubled in one experiment compared to the other two.
Additional complications using IVW can occur in the presence
of missing data, and when sample sizes are extremely small,
e u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 11–19 17
Fig. 3 – Results from the simulation study. Left: for all levels of false discovery rate control targeted (1–10%, x-axis), the
empirical Bayes approach using moderated test statistic produces larger lists of proteins declared differentially expressed
(y-axis), thus detecting more  truly differentially expressed proteins while maintaining proper error control. Right: the same
results presented in a ROC curve. For all false positive rates (0.5–10%, x-axis), the true positive rate (y-axis, black) is
substantially higher when using moderated test statistics, yielding a large difference in sensitivity (y-axis, green). (For
interpretation of the references to colour in this ﬁgure legend, th
false positive rate
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50% fold change  /  ordinary  /  complete
50% fold change  /  ordina ry  /  incomplete
25% fold change  /  mode rated  /  complete
25% fold change  /  mode rated  /  incomplete
25% fold change  /  ordina ry  /  complete
25% fold change  /  ordina ry  /  incomplete
Fig. 4 – Results from the simultaneous analysis of three
simulated iTRAQ experiments using the linear model in
Eq. (8). For all false positive rates (0.5–10%, x-axis)
considered, the true positive rate (y-axis) is substantially
higher when using the moderated test statistics (blue)
instead of the ordinary test statistics (red). Compared were
fold changes of 50% (circles) and 25% (squares), with
complete data (solid symbol) or 10% missing in each
experiment (open symbol). (For interpretation of the
references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)e reader is referred to the web version of this article.)
as the actual number of possible permutations will be very
low as well. Thus, LIMMA provides a more  convenient and
powerful framework to analyze such data than IVW.
The existence of missing data is largely owed to the nature
of the methods used in proteomic studies, as peptide and pro-
tein identiﬁcation between experiments can vary, sometimes
substantially [38–41]. Although missing values for peptides
and proteins due to biological differences are of scientiﬁc
interests, these missing values can also be a nuisance aris-
ing from technical issues. Low or missing peptide intensities
observed by the mass spectrometer can occur due to low pep-
tide abundance, low peptide-dependent ionization efﬁciency,
or the peptide signal distributed across multiple peptide
charge states or different modiﬁed forms of the peptide. Pep-
tide interactions with columns or other peptides in complex
peptide mixtures or small differences in instrument ion samp-
ling contribute to inconsistent peptide detection and missing
values when comparing repeat MS analyses of the same sam-
ple. In multiplex analyses, such as isobaric mass tagging,
missing values can also occur from signal dilution due to a low
abundance peptide being present in one sample but a much
lower abundance or absence in the other samples.
In this manuscript we also explained the effects of such
missing data on the statistical inference with LIMMA, which
performs a complete case analysis contrasting the cases to the
controls within experiment. The amount of variance shrink-
age depends on the actual observed experimental degrees of
freedom – the more  data (samples) are observed for a protein,
the less the shrinkage towards the common mean variance.
Missing data generally results in a loss of power to detect dif-
ferentially expressed proteins, and depending on the nature
of the missingness, can also introduce bias and affect the
type I error [42,43]. In proteomic studies the missingness rate
is commonly related to abundance [38,39]. However, in data
o m i c
r18  e u  p a o p e n p r o t e 
from multiple isobaric mass labelled proteomic experiments
such as 8-plex iTRAQ we observe that the reporter ion inten-
sity is usually observed in all channels within an experiment,
or in none. That is, when a peptide is identiﬁed and quan-
tiﬁed, the data are usually complete for all samples within
an experiment [11]. Thus, the rate of missingness is much
stronger related to the sampling method used by the instru-
ment (i.e., experiment ID) than absolute abundance, let alone
relative abundance (fold change). For other types of experi-
ments such as label-free quantiﬁcation it might be necessary
however to address the missing data explicitly for example
using imputation methods [44–46] before employing empiri-
cal Bayes methods, since the missingness pattern might be
strongly related to protein abundance. This would violate the
notion of “missingness completely at random”, an implicit
assumption in complete case analyses [42,43].
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